GlassScriptPhysician profile
Harinoor Mann
NPI 1306332002
$4,797.28
in general payments reported to CMS, 2019-2025
35 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $14.06 · 2021: $441 · 2022: $775 · 2023: $312 · 2024: $1,138 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,902 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.85 |
| Education | $101.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $572.18 | 2022 | |
| Abbvie INC. | $560.16 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $555.09 | 2019-2025 | Ultomiris |
| Livanova USA, INC. | $308.79 | 2019-2021 | |
| Pfizer INC. | $270.24 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $259.73 | 2019-2025 | |
| Ucb, INC. | $213.30 | 2019-2025 | Zilbrysq, Briviact |
| Genentech USA, INC. | $209.25 | 2020-2025 | Ocrevus Zunovo |
| Vanda Pharmaceuticals INC. | $187.65 | 2025 | Ponvory |
| Axsome Therapeutics, INC. | $168.13 | 2025 | Symbravo |
| Lilly USA, LLC | $151.69 | 2024-2025 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $134.50 | 2022-2025 | |
| Genzyme Corporation | $125.00 | 2021 | |
| Stryker Corporation | $110.44 | 2023 | Axsos |
| Biohaven Pharmaceuticals, INC. | $104.50 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $100.31 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Argenx US, INC. | $99.86 | 2024-2025 | Vyvgart Hytrulo |
| Averitas Pharma INC. | $86.99 | 2023-2025 | Qutenza |
| Takeda Pharmaceuticals U.S.A., INC. | $79.28 | 2024-2025 | Hyqvia |
| Eisai INC. | $74.68 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $57.63 | 2025 | |
| Amneal Pharmaceuticals LLC | $57.59 | 2025 | Crexont |
| Impel Pharmaceuticals LLC | $43.15 | 2025 | Trudhesa |
| Tanabe Pharma America, INC. | $34.78 | 2024 | |
| Tg Therapeutics, INC. | $27.60 | 2025 | |
| Lundbeck LLC | $26.93 | 2025 | Vyepti |
| Cycle Pharmaceuticals INC | $24.42 | 2024 | Ormalvi |
| Biogen, INC. | $22.96 | 2025 | Vumerity, Tysabri |
| Kyowa Kirin, INC. | $22.45 | 2024 | Nourianz |
| Celgene Corporation | $21.36 | 2024 | Zeposia |
| Amylyx Pharmaceuticals, INC. | $20.00 | 2024 | Relyvrio |
| Alnylam Pharmaceuticals INC. | $18.18 | 2025 | Onpattro |
| Janssen Pharmaceuticals, INC | $17.51 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $16.30 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $14.65 | 2024 | Dysport |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harinoor Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.